CytomX Therapeutics, Inc. (CTMX): Earnings News

CTMX – Seeing EPS loss estimates beat range from $0.42-$0.49. Beats on revenues.


Key Facts Surrounding This News Item


  • CTMX had a POWR Rating of A (Strong Buy) coming into today.
  • CTMX was 6.98% above its 10-Day Moving Average coming into today.
  • CTMX was 11.95% above its 20-Day Moving Average coming into today.
  • CTMX was 22.51% above its 50-Day Moving Average coming into today.
  • CTMX was 37.90% above its 100-Day Moving Average coming into today.
  • CTMX was 65.65% above its 200-Day Moving Average coming into today.
  • CTMX had returned +53.29% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About CytomX Therapeutics, Inc. (CTMX)


CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California. View our full CTMX ticker page with ratings, news, and more.

CTMX at a Glance

CTMX Current POWR Rating™
Overall POWR Rating™
CTMX Current Price $14.86 1.00%
More CTMX Ratings, Data, and News

CTMX Price Reaction

The day of this event (Mar. 7, 2018)
CTMX Closing Price$33.87 4.67%
CTMX Volume398,200
24.86% from avg
Leading up to this event
CTMX 1-mo return15.57%
After this event
CTMX 1-day return0.37%
CTMX 3-day return5.44%
CTMX 5-day return4.91%

CTMX Price Chart


The Top Stocks For 2019

More CytomX Therapeutics, Inc. (CTMX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CTMX News
Page generated in 0.9405 seconds.